Sangamo Therapeutics Sees Unusually Large Options Volume (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the target of some unusual options trading on Tuesday. Investors purchased 6,620 call options on the company. This is an increase of approximately 173% compared to the average volume of 2,429 call options.

Sangamo Therapeutics Stock Up 27.3 %

Shares of Sangamo Therapeutics stock opened at $1.54 on Thursday. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.77. The stock has a market cap of $320.66 million, a P/E ratio of -1.12 and a beta of 1.23. The business’s 50 day moving average is $0.86 and its 200-day moving average is $0.66.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. The company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $11.40 million. On average, sell-side analysts expect that Sangamo Therapeutics will post -0.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SGMO. StockNews.com began coverage on Sangamo Therapeutics in a research report on Sunday, July 28th. They issued a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $2.67.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System raised its stake in Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 23,650 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Sangamo Therapeutics in the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Sangamo Therapeutics in the 2nd quarter valued at $89,000. Vontobel Holding Ltd. grew its holdings in Sangamo Therapeutics by 412.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 241,440 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Sangamo Therapeutics in the 1st quarter valued at $331,000. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.